查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609617

勃起功能障碍药物市场规模、份额、趋势分析报告：依产品、剂型、地区、细分市场预测，2025-2030 年

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

勃起功能障碍药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2025年至2030年全球勃起功能障碍药物市场将以9.13%的复合年增长率成长，2030年达到49亿美元。

勃起功能障碍的日益流行预计将有助于市场的成长。根据欧洲泌尿系统的数据，2020 年欧洲 40-70 岁男性族群中 ED 的总体盛行率约为 52%。根据波士顿大学医学院的数据，大约 22.0% 的 40 多岁男性和 49.0% 的 70 多岁男性患有勃起功能障碍。因此，预计在预测期内，老年人口的增加将增加 ED 的盛行率，并有望为市场创造有利的成长机会。

礼来公司透过礼来公司病患支援计画 (LPSP) 提供低成本药物来帮助 ED 患者。该计划为加拿大合格的未投保 ED 患者提供经济援助，并且该计划可能需要註册。因此，犀利士品牌版中此类援助计画的存在可能会使低收入患者更负担得起，也可能导致收益增加。此外，公司正在采取联盟和伙伴关係等倡议，在国外市场製造和商业化其产品。例如，2022 年 1 月，Petros Pharmaceuticals, Inc. 与全球受託製造厂商(CDMO) 合作，进行阿伐那非锭剂的商业生产。此次合作旨在取代与 Vivas 的现有合约并提供持续的产品供应。

此外，根据国家医学图书馆（2021）的数据，四川海丝古药业有限公司在中国当地开展了一项评估 Stendra 对 ED 患者安全性和有效性的 3 期临床试验。临床试验结果显示，两种剂量的 Stendra 100mg 和 200mg 对中国 ED 患者的治疗效果有所改善。这项临床疗效的证明可能会加强 Strenda (Avanafil) 的市场地位。然而，对勃起功能障碍缺乏认识、对治疗感到羞耻、假阳性理论、围绕疾病的社会耻辱、缺乏谨慎等可能会抑制市场成长。根据欧洲泌尿系统协会（EAU）的一项调查，只有18%的西班牙人听说过ED治疗，而68.0%的人相信其有效性。

勃起功能障碍药物市场报告亮点

  • 按产品划分，由于威而钢在全球范围内的供应以及 ED 患者对该产品的认知度不断提高，威而钢细分市场将在 2024 年占据最大的市场占有率。
  • 北美主导勃起功能障碍药物市场，2024年占50.54%的销售份额。这是由于该地区的高疾病负担、强大的医疗基础设施以及新治疗产品的快速核准。
  • 2024年，口服市场占有率，为84.03%。口服给药因其方便、非侵入性和广泛的患者偏好而成为市场的主导部分。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章勃起功能障碍药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 勃起功能障碍药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章勃起功能障碍药物市场：产品评估与趋势分析

  • 细分仪表板
  • 勃起功能障碍药物市场：产品波动分析
  • 勃起功能障碍药物市场：按产品分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 威而钢（柠檬酸Sildenafil）
  • 犀利士（他达拉非）
  • Stendra/Spedra（阿伐那非）
  • Jydena（Udenafil）
  • 其他药品

第五章勃起功能障碍药物市场：给药方法的估计与趋势分析

  • 细分仪表板
  • 勃起功能障碍药物市场：给药方法变化分析
  • 勃起功能障碍药物市场：按给药方法分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 口服给药方法
  • 给药方法 注射
  • 其他给药方法

第六章 勃起功能障碍药物市场：区域估计与趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 2024 年企业市场占有率分析
  • 主要企业简介
    • Bayer AG
    • Lilly
    • GlaxoSmithKline PLC
    • Petros Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd
    • Lupin Limited
    • Futura Medical
    • Cure Pharmaceutical
    • 23andMe
    • Hims &Hers Health, Inc.
    • RO
    • BlueChew
    • GoodRx, Inc.
Product Code: 978-1-68038-604-2

Erectile Dysfunction Drugs Market Growth & Trends:

The global erectile dysfunction drugs market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights:

  • By product, the viagra segment held the largest market share in 2024 due to the worldwide availability of Viagra and increased awareness about the product among ED patients
  • North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 50.54% in 2024, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.
  • The oral mode segment accounted for the largest market share of 84.03% in 2024. The oral mode of administration is a dominant segment in the market, driven by its convenience, non-invasive nature, and widespread patient preference

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mode of Administration
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Erectile Dysfunction Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of erectile dysfunction
      • 3.2.1.2. Rising geriatric population
      • 3.2.1.3. Increasing research & development (R&D)
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of healthcare infrastructure and manufacturing errors
      • 3.2.2.2. Lack of awareness about erectile dysfunction
  • 3.3. Erectile Dysfunction Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Erectile Dysfunction Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Erectile Dysfunction Drugs Market: Product Movement Analysis
  • 4.3. Erectile Dysfunction Drugs Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Viagra (sildenafil citrate)
    • 4.5.1. Viagra (sildenafil citrate) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cialis (Tadalafil)
    • 4.6.1. Cialis (Tadalafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Stendra/Spedra (avanafil)
    • 4.7.1. Stendra/Spedra (avanafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Zydena (udenafil)
    • 4.8.1. Zydena (udenafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Other Drugs
    • 4.9.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Erectile Dysfunction Drugs Market: Mode of Administration Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Erectile Dysfunction Drugs Market: Mode of Administration Movement Analysis
  • 5.3. Erectile Dysfunction Drugs Market by Mode of Administration Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Oral Mode of Administration
    • 5.5.1. Oral Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Injectable Mode of Administration
    • 5.6.1. Injectable Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Modes of Administration
    • 5.7.1. Other Modes of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Erectile Dysfunction Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Bayer AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Lilly
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. GlaxoSmithKline PLC
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Petros Pharmaceuticals, Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Pfizer Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Teva Pharmaceutical Industries Ltd
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Lupin Limited
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Futura Medical
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Cure Pharmaceutical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. 23andMe
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Hims & Hers Health, Inc.
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. RO
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. BlueChew
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. GoodRx, Inc.
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 4. Global Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 5. North America Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 6. North America Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 7. U.S. Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 8. U.S. Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 9. Canada Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 10. Canada Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 11. Mexico Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 12. Mexico Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 13. Europe Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 14. Europe Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 15. UK Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 16. UK Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 17. Germany Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 18. Germany Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 19. France Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 20. France Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 21. Italy Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 22. Italy Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 23. Spain Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 24. Spain Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 25. Denmark Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 26. Denmark Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 27. Sweden Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 28. Sweden Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 29. Norway Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 30. Norway Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 31. Asia Pacific Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 32. Asia Pacific Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 33. Japan Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 34. Japan Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 35. China Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 36. China Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 37. India Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 38. India Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 39. Australia Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 40. Australia Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 41. South Korea Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 42. South Korea Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 43. Thailand Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 44. Thailand Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 45. Latin America Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 46. Latin America Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 47. Brazil Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 48. Brazil Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 49. Argentina Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 50. Argentina Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 51. Middle East & Africa Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 52. Middle East & Africa Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 53. South Africa Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 54. South Africa Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 55. Saudi Arabia Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 56. Saudi Arabia Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 57. UAE Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 58. UAE Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)
  • Table 59. Kuwait Erectile Dysfunction Drugs market, by Product, 2018 - 2030 (USD Million)
  • Table 60. Kuwait Erectile Dysfunction Drugs market, by Mode of Administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Erectile Dysfunction Drugs market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Erectile Dysfunction Drugs market, Product outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 12 Viagra (sildenafil citrate) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Cialis (tadalafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Levitra/Staxyn (vardenafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Stendra/Spedra (avanafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Zydena (udenafil) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Other drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Erectile Dysfunction Drugs market, Mode of Administration outlook key takeaways 2024 & 2030 (USD Million)
  • Fig. 19 Oral mode of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million
  • Fig. 20 Injectable mode of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million
  • Fig. 21 Other modes of administration market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 North America erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Spain erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Norway erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Denmark erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Sweden erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 China erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 South Korea erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Middle East and Africa erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait erectile dysfunction drugs market estimates and forecasts, 2018 - 2030 (USD Million)